Home › Compare › DUSYF vs PFE

DUSYF vs PFE: Dividend Comparison 2026

DUSYF yields 20000000.00% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DUSYF wins by $4.875981653489057e+49M in total portfolio value
10 years
DUSYF
DUSYF
● Live price
20000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.875981653489057e+49M
Annual income
$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00
Full DUSYF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — DUSYF vs PFE

📍 DUSYF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDUSYFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DUSYF + PFE cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
DUSYF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DUSYF
Annual income on $10K today (after 15% tax)
$1,700,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$41,445,436,407,424,570,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, DUSYF beats the other by $41,445,436,407,424,570,000,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DUSYF + PFE for your $10,000?

DUSYF: 50%PFE: 50%
100% PFE50/50100% DUSYF
Portfolio after 10yr
$2.4379908267445285e+49M
Annual income
$24,379,668,474,955,630,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

DUSYF
No analyst data
Altman Z
-6.1
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DUSYF buys
0
PFE buys
0
No recent congressional trades found for DUSYF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDUSYFPFE
Forward yield20000000.00% ✓6.13%
Annual dividend / share$2.00 ✓$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2% ✓
Portfolio after 10y$4.875981653489057e+49M$49.6K ✓
Annual income after 10y$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00 ✓$26,258.71
Total dividends collected$4.875978515990276e+49M$58.3K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DUSYF vs PFE ($10,000, DRIP)

YearDUSYF PortfolioDUSYF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$2,000,010,700$2,000,000,000.00$9,153$693.39+$2000.00M → DUSYF
2$373,835,915,712,384$373,833,775,700,934.50$8,593$849.25+$373835915.70M → DUSYF
3$65,304,953,364,964,970,000$65,304,553,360,535,160,000.00$8,336$1,066.78+$65304953364964.96M → DUSYF
4$10,661,728,832,755,500,000,000,000$10,661,658,956,455,399,000,000,000.00$8,437$1,384.80+$10661728832755499008.00M → DUSYF
5$1,626,767,783,781,495,000,000,000,000,000$1,626,756,375,731,643,800,000,000,000,000.00$9,013$1,875.40+$1.626767783781495e+24M → DUSYF
6$231,974,330,054,625,100,000,000,000,000,000,000$231,972,589,413,096,470,000,000,000,000,000,000.00$10,306$2,680.72+$2.319743300546251e+29M → DUSYF
7$30,915,106,403,922,057,000,000,000,000,000,000,000,000$30,914,858,191,388,900,000,000,000,000,000,000,000,000.00$12,820$4,101.38+$3.0915106403922057e+34M → DUSYF
8$3,850,507,985,839,278,000,000,000,000,000,000,000,000,000,000$3,850,474,906,675,425,000,000,000,000,000,000,000,000,000,000.00$17,673$6,826.70+$3.8505079858392777e+39M → DUSYF
9$448,210,261,035,314,200,000,000,000,000,000,000,000,000,000,000,000$448,206,140,991,769,400,000,000,000,000,000,000,000,000,000,000,000.00$27,543$12,591.86+$4.4821026103531426e+44M → DUSYF
10$48,759,816,534,890,570,000,000,000,000,000,000,000,000,000,000,000,000,000$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00$49,560$26,258.71+$4.875981653489057e+49M → DUSYF

DUSYF vs PFE: Complete Analysis 2026

DUSYF — Stock

Duesenberg Technologies Inc. engages in the information technology business. The company offers VGrab Applications, a free mobile voucher application for smartphones using the Android and Apple iOS operating systems that allows users to redeem vouchers on their smartphones at various retailers and merchants. It also provides Vmore Platform and SMART Systems. In addition, the company develops electric vehicles under the Duesenberg brand. The company was formerly known as VGrab Communications Inc. and changed its name to Duesenberg Technologies Inc. in December 2020. The company was incorporated in 2010 and is based in Penang, Malaysia.

Full DUSYF Calculator →

PFE — Healthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this DUSYF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DUSYF vs SCHDDUSYF vs JEPIDUSYF vs ODUSYF vs KODUSYF vs MAINDUSYF vs JNJDUSYF vs MRKDUSYF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.